Johnson & Johnson gets CDSCO Panel for additional indication of Amivantamab Liquid Concentrate for Infusion Dr. Divya Colin12 April 2025 5:45 AM ISTNew Delhi: In a significant development, the drug major Johnson and Johnson has got the go-ahead from the Subject Expert Committee (SEC) functional...
Janssen-Cilag International gets European Commission nod for subcutaneous Rybrevant for advanced EGFR-mutated non-small cell lung cancer Ruchika Sharma8 April 2025 11:30 AM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) for an extension...
European Commission approves Janssen-Cilag International Rybrevant, Lazcluze combo for first-line treatment of lung cancer Ruchika Sharma31 Dec 2024 11:30 AM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has approved a Type II...
Johnson & Johnson Gets CDSCO Panel Nod to Study anti-cancer drug Amivantamab Dr. Divya Colin26 Oct 2024 5:30 PM ISTNew Delhi: The drug major Johnson & Johnson has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
EMA Committee recommends Rybrevant in combo with chemotherapy for adult patients with lung cancer after failure of prior therapy Ruchika Sharma4 Aug 2024 11:00 AM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
CDSCO Panel Approves Johnson and Johnson's Protocol Amendment Proposal to study anti-cancer drug Amivantamab Dr. Divya Colin14 July 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major...
JnJ submits application to USFDA for Subcutaneous amivantamab for patients with EGFR-mutated non-small cell lung cancer Ruchika Sharma19 Jun 2024 3:56 PM ISTRaratin: Johnson & Johnson has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...
JnJ gets positive CHMP opinion for Rybrevant, chemotherapy combo for first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations Ruchika Sharma28 April 2024 12:30 PM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
CDSCO Panel Approves J&J's Protocol Amendment Proposal For Amivantamab, Lazertinib combination Dr. Divya Colin14 April 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel grants J&J Protocol Amendment proposal to study anticancer drug Amivantamab and Lazertinib Dr. Divya Colin9 Jan 2024 5:45 PM ISTNew Delhi: Regarding the study of Amivantamab and Lazertinib in combination with platinum-based chemotherapy compared with platinum-based chemotherapy...
Janssen seeks EMA marketing nod for Lazertinib plus Rybrevant for EGFR-Mutated Non Small Cell Lung Cancer Ruchika Sharma25 Dec 2023 3:30 PM ISTBelgium: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a marketing authorisation application...
Johnson & Johnson Gets CDSCO Panel Okay To Study Anti-cancer Drug Lazertinib/Amivantamab Dr. Divya Colin4 Nov 2022 6:00 PM ISTNew Delhi: Pharmaceutical major Johnson and Johnson has got green signal from the Subject Expert Committee (SEC) functional under the Central Drug...
